Open AccessFarnesylthiosalicylic Acid-Loaded Albumin Nanoparticle Alleviates Renal Fibrosis by Inhibiting Ras/Raf1/p38 Signaling Pathway
Author(s) -
Hui Huang,
Qinhui Liu,
Ting Zhang,
Jinhang Zhang,
Jian Zhou,
Xiandan Jing,
Qin Tang,
Cuiyuan Huang,
Zijing Zhang,
Yingnan Zhao,
Guorong Zhang,
Jiamin Yan,
Yan Xia,
Ying Xu,
Jiahui Li,
Yanping Li,
Jinhan He
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s318124
Subject(s) - in vivo , fibrosis , pharmacology , medicine , kidney , albumin , kidney disease , cancer research , chemistry , pathology , biology , microbiology and biotechnology
Renal fibrosis is the common pathway in chronic kidney diseases progression to end-stage renal disease, but to date, no clinical drug for its treatment is approved. It has been demonstrated that the inhibitor of proto-oncogene Ras, farnesylthiosalicylic acid (FTS), shows therapeutic potential for renal fibrosis, but its application was hindered by the water-insolubility and low bioavailability. Hence, in this study, we improved these properties of FTS by encapsulating it into bovine serum albumin nanoparticles (AN-FTS) and tested its therapeutic effect in renal fibrosis.